Antares Pharma Appoints Peter J. Graham, Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Offi...
July 14 2015 - 7:00AM
Business Wire
Antares Pharma, Inc. (NASDAQ:ATRS) today announced the
appointment of Peter J. Graham, Esq., to the position of Senior
Vice President, General Counsel, Human Resources, Chief Compliance
Officer and Corporate Secretary. Mr. Graham will report to Eamonn
P. Hobbs, President and Chief Executive Officer.
"With an extensive background of legal health care experience in
contract negotiations, mergers and acquisitions, SEC reporting,
compliance and general corporate matters, I believe Peter will add
value to Antares Pharma," said Eamonn P. Hobbs. "His legal
expertise and proven global strategy management of both publicly
and privately held pharmaceutical and medical device companies will
be an added asset to the Company. We are excited to welcome Peter
to the Antares team."
The Company also announced the departure of Jennifer Evans
Stacey, Esq., the Company's Senior Vice President, General Counsel,
Human Resources and Secretary and Chief Compliance Officer.
"On behalf of the Antares Board of Directors and Executive
Leadership Team, I would like to thank Ms. Stacey for her many
contributions to the Company," continued Mr. Hobbs. "Jennifer
played an important role in the settlement of the Medac litigation
and was integral to the successful integration of the Company’s
first in-house salesforce. I’d like to personally wish Jennifer
well in all future endeavors."
Mr. Graham was most recently Executive Vice President, General
Counsel, Chief Compliance Officer and Global Human Resources of
Delcath Systems, Inc., where he directed the global legal,
compliance and human resource functions. Prior to Delcath, Mr.
Graham was Vice President, General Counsel and a member of the
Executive Committee of ACIST Medical Systems, Inc., a global
company specializing in diagnostic and therapeutic medical devices
for cardiology and radiology. There, he led the corporate accounts
and global legal affairs of the company, playing a significant role
in helping to expand the company's corporate contract business and
international distribution network and the $80 million acquisition
of HLT, Inc. Prior to that, Mr. Graham spent 11 years at E-Z-EM,
Inc., a global medical device and pharmaceutical company
specializing in CT and MR imaging solutions. During his tenure at
E-Z-EM, Mr. Graham held various senior management positions serving
as its Senior Vice President, Chief Legal Officer, Global Human
Resources and Secretary from 2005 until 2008. Mr. Graham played a
key role in the sale of E-Z-EM in 2008 leading and coordinating the
legal and investment banking activities associated with the sale.
He also managed the legal affairs of AngioDynamics, Inc., then a
wholly owned subsidiary of E-Z-EM from 1997 until its initial
public offering and tax free spin off in 2004.
Mr. Graham was on the Board of Directors of AngioDynamics from
2006 to 2007, and was instrumental in the company's successful $75
million follow-on offering, and its acquisition of Rita Medical
Systems, Inc. for $220 million during that time frame.
Before his time with E-Z-EM, Mr. Graham was an associate at
Segal and Lax, P.C. He earned his J.D. at Yeshiva University's
Benjamin N. Cardozo School of Law in 1995, and his B.A. at the
University of Wisconsin-Madison.
About Antares Pharma
Antares Pharma focuses on self-administered parenteral
pharmaceutical products. The Company’s product, OTREXUP™
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. Antares
Pharma is also developing QuickShot® Testosterone for testosterone
replacement therapy, and VIBEX® Sumatriptan for the acute treatment
of migraines. The Company's technology platforms include VIBEX®
disposable auto injectors, disposable multi-use pen injectors and
reusable needle-free injectors. Antares Pharma has a multi-product
deal with Teva Pharmaceutical Industries, Ltd. that includes VIBEX®
epinephrine, exenatide multi-dose pen, and another undisclosed
multi-dose pen. Our reusable needle-free injector for use with
human growth hormone (hGH) is sold worldwide by Ferring B.V.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995
This press release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, including statements made with
respect to the value added by Peter Graham; development of products
for the Company and for alliance partners; and other statements
regarding matters that are not historical facts, and involve
predictions. These statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance, achievements or prospects to be materially different
from any future results, performance, achievements or prospects
expressed in or implied by such forward-looking statements. In some
cases you can identify forward-looking statements by terminology
such as "may", "will", "should", "would", "expect", "intend",
"plan", "anticipate", "believe", "estimate", "predict",
"potential", "seem", "seek", "future", "continue", or "appear" or
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Such forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties that may
cause actual results to differ materially from those anticipated by
the forward-looking statements. Additional information concerning
these and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2014, and in
the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. All forward-looking
statements are based on information currently available to the
Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of this press
release, except as required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150714005426/en/
Antares Pharma, Inc.Jack Howarth, 609-359-3016Vice President,
Corporate Affairsjhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024